The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy-Reference-Cited by-同舟云学术

The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy

Published:2015-06 Issue:6 Volume:67 Page:1009-1016
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Zumsteg Zachary S.,Spratt Daniel E.,Romesser Paul B.,Pei Xin,Zhang Zhigang,Polkinghorn William,McBride Sean,Kollmeier Marisa,Yamada Yoshiya,Zelefsky Michael J.

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J Clin,2012

3. Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment;Elliott;J Urol,2012

4. Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations;Rosenbaum;J Natl Compr Canc Netw,2004

5. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer;Spratt;Int J Radiat Oncol Biol Phys,2013

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Positron emission tomography computed tomography in the diagnosis of prostate cancer;Karnataka Medical Journal;2024-09-03

2. Integrative analysis regarding the correlation between collagen-related genes and prostate cancer;BMC Cancer;2024-08-22

3. Utilizing Liquid–liquid phase separation-related lncRNAs to predict the prognosis and treatment response of PCa;Discover Oncology;2024-08-16

4. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer;Nature Reviews Urology;2024-08-07

5. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy;Cancers;2024-07-26